Scholarlink

<p>Breast cancer continues to be the leading cause of cancer-related fatalities and illnesses all over the world; thus, understanding its complex biology and developing improved treatment strategies requires a great deal of investigation. Examining tumor growth, drug response, and treatment effectiveness involves using experimental models. The in vitro and in vivo models employed in breast cancer research are extensively reviewed in terms of their applications, advantages, and disadvantages in this paper. Researchers can use in vitro models to study drug screening, molecular pathways, and how cancer cells behave in a controlled environment. These models include two-dimensional monolayer cultures, three-dimensional spheroids, organoids, and microfluidic systems. Although&#xa0;these models can enable high-throughput analytical and mechanistic studies, they cannot mimic the complexity of the tumor microenvironment. It is beneficial to study tumor heterogeneity, metastasis, and immune interactions using genetically engineered mouse models, patient-derived xenografts, and syngeneic models. Differences between species and ethical concerns provide challenges. With new methods like CRISPR/Cas9 gene editing, humanized mouse models, 3D bioprinting, and patient-derived organoids, the gap between preclinical findings and clinical applications is getting smaller. This makes experimental models more useful in the real world. Combining these models with computational techniques such as in vitro–in vivo extrapolation and physiologically based pharmacokinetic modeling helps increase the accuracy of drug development forecasts. This paper underlines the need for experimental models in furthering breast cancer research and points out ways to improve these systems. Working on present constraints using multidisciplinary cooperation and technical innovation will help us understand&#xa0;breast cancer better and guide us toward developing more potent treatment strategies.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advancing breast cancer research: a comprehensive review of in vitro and in vivo experimental models

  • 期刊论文

  • 发表日期：

    2025年7月9日

查看全文
  • Shubhashree Das,
  • Soumyaranjan Sahoo,
  • Sovan Pattanaik,
  • Rajat Kumar Prusty,
  • Binapani Barik,
  • Bhabani Sankar Satapathy,
  • Gurudutta Pattnaik

摘要

Breast cancer continues to be the leading cause of cancer-related fatalities and illnesses all over the world; thus, understanding its complex biology and developing improved treatment strategies requires a great deal of investigation. Examining tumor growth, drug response, and treatment effectiveness involves using experimental models. The in vitro and in vivo models employed in breast cancer research are extensively reviewed in terms of their applications, advantages, and disadvantages in this paper. Researchers can use in vitro models to study drug screening, molecular pathways, and how cancer cells behave in a controlled environment. These models include two-dimensional monolayer cultures, three-dimensional spheroids, organoids, and microfluidic systems. Although these models can enable high-throughput analytical and mechanistic studies, they cannot mimic the complexity of the tumor microenvironment. It is beneficial to study tumor heterogeneity, metastasis, and immune interactions using genetically engineered mouse models, patient-derived xenografts, and syngeneic models. Differences between species and ethical concerns provide challenges. With new methods like CRISPR/Cas9 gene editing, humanized mouse models, 3D bioprinting, and patient-derived organoids, the gap between preclinical findings and clinical applications is getting smaller. This makes experimental models more useful in the real world. Combining these models with computational techniques such as in vitro–in vivo extrapolation and physiologically based pharmacokinetic modeling helps increase the accuracy of drug development forecasts. This paper underlines the need for experimental models in furthering breast cancer research and points out ways to improve these systems. Working on present constraints using multidisciplinary cooperation and technical innovation will help us understand breast cancer better and guide us toward developing more potent treatment strategies.

Graphical abstract